Monocyte-derived microparticles play an important role in the pathogenesis of diabetic vasculopathy, and angiotensin II receptor blocker and statin have been shown to have a beneficial effect on the angiopathies of hypertension and hyperglycemia in patients with type 2 diabetes mellitus. However, the interaction between angiotensin II receptor blocker and statin, and monocyte-derived microparticles in atherosclerosis is poorly understood. The effects of losartan and simvastatin on circulating concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion markers were studied in hypertensive patients with or without type 2 diabetes mellitus. Monocyte-derived microparticles were measured by flow cytometry, and levels of serum chemokines (MCP-1 and RANTES) and soluble adhesion markers (sP-selectin and sVCAM-1) were measured by enzyme-linked immunosorbent assay. Losartan decreased both the systolic and diastolic blood pressure in hypertensive patients with and without type 2 diabetes mellitus. The concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients who also had type 2 diabetes mellitus vs. those who did not. The administration of angiotensin II receptor blocker decreased the circulating concentration of all these markers. In addition, all markers were decreased by combination therapy, and monocyte-derived microparticles were decreased more with combination therapy with losartan and simvastatin than monotherapy with losartan. The administration of angiotensin II receptor blocker inhibited monocyte-derived microparticle generation and suggests that angiotensin II is intimately related to vascular changes that occur in type 2 diabetes mellitus. Combination therapy with a statin and angiotensin II receptor blocker might be valuable as anti-atherosclerotic therapy in patients with type 2 diabetes mellitus and nephropathy.
Uusitupa MI, Niskanen LK, Siitonen O, et al.Ten years cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia1993;36:1175.
2.
Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care2001;24:1167.
3.
Lopes-Virella MF, Virella G.Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes1992;41 (Suppl 2):86.
4.
Carmassi F, Morale M, Puccetti R, et al.Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res1992;67:643.
5.
Steiner M, Reinhardt KM, Krammer B, et al.Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost1994;72:979.
6.
Cominacini L, Pasini AF, Garbin U, et al.E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: Possible role of oxidative stress. Diabetologia1997;40:584.
7.
Johnson RB. Monocytes and macrophages. N Engl J Med1988;318:747.
8.
Beekhuizen H, van Furth R.Monocyte adherence to human vascular endothelium. J Leukoc Biol1993;54:363.
9.
Jonasson L, Holm J, Bondjers G, et al.Regional accumlation of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis1986;6:131.
10.
Ferro D, Parrotto S, Basili S, et al.Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol2000;36:427.
11.
Serrano CV, Yoshida VM, Venturinelli ML, et al.Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis2001;157:505.
12.
Rezaie-Majid A, Maca T, Bucek RA, et al.Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol2002;22:1194.
13.
Ceriello A, Taboga C, Tonutti L, et al.Evidence for an independent and cumulative effect of postprandial hyper-triglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation2002;106:1211.
14.
Drake TA, Ruf W, Morrissey JH, et al.Functional tissue factor is entirely surface expressed on lipopolysaccharide stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol1989;109:389.
15.
Wilcox JN, Smith KM, Schwartz SM, et al.Localization of tissue factor in normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA1989;86:2839.
16.
Osnes LTN, Westvik AB, Kieruf P.Procoagulant and profibrinolytic activities of cryopreserved human monocytes. Thromb Res1994;76:373.
17.
Ferro D, Basili S, Alessandri C, et al.Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis2000;149:111.
18.
Satta N, Toti F, Feugeas O, et al.Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol1994;153:3245.
19.
Omoto S, Nomura S, Shouzu A, et al.Detection of monocyte-derived microparticles in patients with type II diabetes mellitus. Diabetologia2002;45:550.
20.
Robinson RA, Worfolk L, Tracy PB. Endotoxin enhances the expression of monocyte prothrombinase activity. Blood1992;79:406.
21.
Pugh JA, Medina RA, Cornell JC, et al.NIDDM is the major cause of diabetic end-stage renal disease: More evidence for a tri-ethnic community. Diabetes1995;44:1375.
22.
Mattock MB, Barnes DJ, Viberti GC, et al.Micro-albuninuria and coronary heart disease in non-insulin-dependent diabetes: An incidence study. Diabetes1998;47:1786.
23.
Ruggenenti P, Schieppati A, Remuzzi G.Progression, remission, regression of chronic renal disease. Lancet2001;357:1601.
24.
Maschio G, Alberti D, Janin G, et al.Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med1996;334:939.
25.
Remuzzi A, Perico N, Amuchastegui CS, et al.Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol1993;4:40.
26.
Cheetham C, Collis J, O’Driscoll G, et al.Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin dependent diabetes. J Am Coll Cardiol2000;36:1461.
27.
The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in diabetes. Hypertension1994;23:145.
28.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert commitee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20:1183.
29.
Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias, Japan Atherosclerosis Society. Guideline for Diagnosis and Treatment of Hyperlipidemias in Adults. Doumyakukouka1997;25:1.
30.
Lindholm LH, Ibsen H, Dahlof B, et al.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endopoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet2002;359:1004.
31.
Kjeldsen SE, Dahlof B, Devereux RB, et al.Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endopoint Reduction (LIFE) substudy. JAMA2002;288:1491.
32.
Shahinfar S, Dickson TZ, Ahmed T, et al.Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL study. Kidney Int2002;82 (Suppl):64.
33.
Wolf G, Schneider A, Helmchen U, et al.AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol1998;6:112.
34.
Strawn WB, Gallagher PE, Tallant EA, et al.Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2) 27 rats. J Cardiovasc Pharmacol1999;33:341.
35.
Hayek T, Aviram M, Heinrich R, et al.Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem Biophys Res Commun2000;273:417.
36.
Jilma B, Li-Saw-Hee FL, Wagner OF, et al.Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci2002;103:131.
37.
Rajagopalan S, Brook R, Mehta RH, et al.Effect of losartan in aging-related endothelial impairment. Am J Cardiol2002;89:562.
38.
Fogari R, Mugellini A, Zoppi A, et al.Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens2002;15:316.
39.
Nomura S, Suzuki M, Katsura K, et al.Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis1995;116:235.
40.
Nomura S, Shouzu A, Omoto S, et al.Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost1998;80:388.
41.
Nomura S, Shouzu A, Omoto S, et al.Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol2000;121:437.
42.
Ross R.Atherosclerosis: An inflammatory disease. N Engl J Med1999;340:115.
43.
Bevilacqua MP, Nelson RM, Mannori G, et al.Endothelialleukocyte adhesion molecules in human disease. Annu Rev Med1994;45:361.
44.
Adams DH, Shaw S.Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet1994;343:831.
45.
Chen XL, Tummala PE, Olbrych MT, et al.Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res1998;83:952.
46.
Kintscher U, Wakino S, Kim S, et al.Angiotensin II induces migration and Pyk2/Paxillin phosphorylation of human monocytes. Hypertension2001;37:587.
47.
Napoleone E, DiSanto A, Camera M, et al.Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res2000;86:139.
48.
Ferro D, Parrotto S, Basili S, et al.Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol2000;36:427.
49.
Teupser D, Bruegel M, Stein O, et al.HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun2001;289:838.
50.
Serrano CV Jr, Yoshida VM, Venturinelli ML, et al.Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis2001;157:505.
51.
Rezaie-Majd A, Maca T, Bucek RA, et al.Simvastatin reduces expression of cytokines, interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol2002;22:1194.
52.
Lefer DJ. Statin as potent antiinflammatory drugs. Circulation2002;106:2041.
53.
Ceriello A, Taboga C, Tonutti L, et al.Evidence for an independent and cumulative effect of postprandial hyper-triglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation2002;106:1211.
54.
Cipollone F, Mezzetti A, Porreca E, et al.Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia—effects of statin therapy. Circulation2002;106:399.
55.
Ferro D, Basili S, Alessandri C, et al.Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis2000;149:111.
56.
Lee IT, Sheu WHH, Lin SY, et al.Simvasatatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabet Complicat2002;16:382.
57.
Plenge JK, Hernandez TL, Weil KM, et al.Simvastatin lowers C-reactive protein within 14 days—an effect independent of low-density lipoprotein cholesterol reduction. Circulation2002;106:1447.
58.
Zoja C, Corna D, Rottoli D, et al.Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int2002;61:1635.
